

89 **Paper alert**

Martin Read & Susmita Hunt

93 **Patent alert**

Scott J Tebbutt & Debabrata Banerjee

98 **Web alert**

Simon Brown & Daniel Jones

Oligonucleotide, antibody and peptide therapeutics

Edited by John Goodchild & Patrick L Iversen

100 **John Goodchild & Daniel Jones**
Editorial overview: Oligonucleotide, antibody and peptide therapeutics

102 **Ehud Ilan, Rachel Eren, Ido Lubin, Ofer Nussbaum, Arie Zauberman & Shlomo Dagan**
The Trimer mouse: A system for generating human monoclonal antibodies and modeling human diseases

110 **Janice M Reichert**
Therapeutic monoclonal antibodies: Trends in development and approval in the US

119 **Levon M Khachigian**
DNAzymes: Cutting a path to a new class of therapeutics

122 **Ekambar R Kandimalla, Dong Yu & Sudhir Agrawal**
Towards optimal design of second-generation immunomodulatory oligonucleotides

130 **Gregory K Reid, Jeffrey M Besterman & A Robert MacLeod**
Selective inhibition of DNA methyltransferase enzymes as a novel strategy for cancer treatment

138 **Gayathri R Devi**
Prostate cancer: Status of current treatments and emerging antisense-based therapies

149 **Georg Sczakiel & Rosel Kretschmer-Kazemi Far**
The role of target accessibility for antisense inhibition

154 **Mayu Iyo, Hiroaki Kawasaki & Kazunari Taira**
Allosterically controllable maxizymes for molecular gene therapy

166 **Naruya Tomita, Ryuichi Morishita, Tetsuya Tomita & Toshio Ogihara**
Potential therapeutic applications of decoy oligonucleotides

171 **Erin E Brachman & Eric B Kmiec**
The 'biased' evolution of targeted gene repair

177 **Alvin W Smith, David O Matson, David A Stein, Douglas E Skilling, Andrew D Kroeker, Tamas Berke & Patrick L Iversen**
Antisense treatment of *Caliciviridae*: An emerging disease agent of animals and humans

185 **Hanns M Lorenz**
Technology evaluation: Adalimumab, Abbott Laboratories
